Can I read The lower risk MDS patient at risk of rapid progression on EtoBox?

The lower risk MDS patient at risk of rapid progression by Moshe Mittelman; Howard S. Oster; Michael Hoffman; Drorit Neumann is a Medicine article available to read on EtoBox.

What is The lower risk MDS patient at risk of rapid progression about?

Most patients with myelodysplastic syndrome (MDS) are classified at diagnosis as having a low/INT-I or INT-II/high risk disease, based on the classical International Prognostic Scoring System (IPSS) criteria. The low/INT-I risk patients are usually managed mildly with supportive care, including red blood cell (RBC) transfusions, erythroid stimulating agents (ESAs), other cytokines (G-CSF, platelet stimulating agents), as well as thalidomide and lenalidomide. Some patients receive immunosuppressive therapy, and iron chelation is indicated in iron overloaded patients. Aggressive approach (hypomethylating agents, chemotherapy and stem cell transplantation) is usually not applied in such patients. Occasionally, we observe a "low risk" patient with rapid progression of disease and poor outcome. Can we identify demographic, clinical, laboratory, cellular-biological and/or molecular parameters that can predict "poor prognostic features" (PPF) in "low risk" MDS patients? Clinical and laboratory parameters have been reported to be associated with poor prognosis, in addition to the known "classical" IPSS criteria. These include older age, male gender, poor performance status, co-morbidities,

Who reads The lower risk MDS patient at risk of rapid progression?

Author

Moshe Mittelman; Howard S. Oster; Michael Hoffman; Drorit Neumann

Publisher

Elsevier Science; Elsevier ; Elsevier Ltd.; Elsevier BV (ISSN 0145-2126)

Published

2010

Language

EN

Field

Medicine (Health Sciences)